Use of traditional Chinese medicine in Chinese patients with coronary heart disease

Biomedical and Environmental Sciences

Volumn 26, Issue 4, 2013, Pages 303-310

  Guo, Xiang Yu ^a   Liu, Jing ^a   Liu, Jun ^a   Li, Hong Juan ^a   Qi, Yue ^a   Qin, Lan Ping ^a   Wang, Miao ^a   Zhao, Dong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Coronary heart disease; Guidelines; Traditional Chinese medicine

Indexed keywords

AGED; ARTICLE; ASIAN; CHINA; CHINESE MEDICINE; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MALE; MIDDLE AGED; PRACTICE GUIDELINE; SECONDARY PREVENTION; STATISTICS; UTILIZATION REVIEW;

CORONARY HEART DISEASE; GUIDELINES; TRADITIONAL CHINESE MEDICINE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; SECONDARY PREVENTION;

MLCS; MLOWN;

EID: 84880231650     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: 10.3967/0895-3988.2013.04.009     Document Type: Article

References (46)

1. Zhang XH, Lu ZL, Liu L. Coronary heart disease in China. Heart, 2008;94, 1126-31.
2. Moran A, Zhao D, Gu D, et al. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. BMC Public Health, 2008;8, 394.
3. Wu Z, Yao C, Zhao D, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China, Part i: morbidity and mortality monitoring. Circulation, 2001;103, 462-8.
4. Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in China: markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circ Cardiovasc dual Outcomes, 2010;3, 243-52.
5. Newby LK, La Pointe NM, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation, 2006;113, 203-12.
6. Clark AM, Hartling L, Vandermeer B, et al. Meta-Analysis: Secondary Prevention Programs for Patients with Coronary Artery Disease. Ann Intern Med, 2005;143, 659-72.
7. Zhao D. Secondary prevention of coronary heart disease in Chinese: differences and pondering. Chinese Journal of Internal Medicine (Zhonghua Nei Ke Za Zhi), 2009;48, 806. (In Chinese)
8. Liu Q, Zhao D, Liu J. Rationale and design of baseline survey of BRIG (Bridging the gap on CAD secondary prevention) project: a multi-provincial implementation study on CAD patients' management in China. Journal of Cardiovascular and Pulmonary Diseases (Xin Fei Xue Guan Bing Za Zhi), 2008;27, 37-41. (In Chinese)
9. Niu S, Zhao D, Zhu J, et al. The association between socioeconomic status of high-risk patients with coronary heart disease and the treatment rates of evidence-based medicine for coronary heart disease secondary prevention in China: Results from the Bridging the Gap on CHD Secondary Prevention in China (BRIG) Project. Am Heart J, 2009;157, 709-15.el.
10. Jin Y, Wang JC, Li ZD, et al. Investigation on the current utilization of anti-platelet drug and blood-activiating Traditional Chinese Medicines in patients with stable angina. Chinese Journal of Gerontology (Zhongguo Lao Nian Xue Za Zhi), 2009;29, 1242-4. (In Chinese)
11. Wei M. How to choose Chinese traditional medicines for coronary heart disease. Chinese Journal of Integrative Medicine on Cardio-/Cerebrovascular Disease (Zhong Xi Yi Jie He Xin Nao Xue Guan Bing Za Zhi), 2008;6, 89-90. (In Chinese)
12. Zhang A, Sun H, Wang Z, et al. Metabolomics towards understanding traditional Chinese medicine. Planta Med, 2010;76, 2026-35.
13. Harmsworth K, Lewith GT. Attitudes to traditional Chinese medicine amongst Western trained doctors in the People's Republic of China. Soc Sci Med, 2001;52, 149-53.
14. Xu ZX, Wang YQ, Liu GP, et al. Clinical Distribution of Traditional Chinese Medicine Syndromes on Cardiovascular Diseases. Mode Tradit Chin Med Mater Med, 2010;12, 888-91.
15. Wu B, Liu M, Liu Wong W, et al. A comparison of the effectiveness between Western medicine and Chinese medicine outpatient consultations in primary care. Complement Ther Med, 2011;19, 264-75.
16. Chen KJ. Certain progress in the treatment of coronary heart disease with traditional medicinal plants in China. Am J Chin Med, 1981;9, 193-6.
17. Jun. Y. Prevention of coronary heart disease. Viewpoints contributed by traditional Chinese medicine. Hygie, 1992;11, 37-8.
18. Liu PH, Wu B. Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke, 2007;38, 1973-9.
19. Wu B, Liu M. How to improve the quality of a clinical trial on traditional Chinese medicine for stroke. Stroke, 2009;40, e641-e2.
20. Xue CC, Zhang AL, Greenwood KM, et al. Traditional Chinese medicine: an update on clinical evidence. J Altern Complement Med, 2010;16, 301-12.
21. Liu H, Liu P. The Advantage of the Clinical Treatment and the Prevention the Cardiovascular Disease. Beijing Journal of Traditional Chinese Medicine (Beijing Zhong Yi), 2007;26, 396-9. (In Chinese)
22. Cheng TO. Cardiovascular effects of Danshen. Int J Cardiol, 2007;121, 9-22.
23. Zhang HT, Jia ZH, Zhang J, et al. No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial). Chin Med J, 2010;123, 2858-64.
24. Xu, H, Chen, KJ. Integrative medicine: the experience from China. Journal of Alternative and Complementary Medicine, 2008;14, 3-7.
25. Chen H, Shi DZ. Inspiration from Years' Recent Clinical Trials and Guidelines of Coronary Artery Disease for Integrative Medicine. Chinese Journal of Integrated Traditional and Western Medicine (Zhongguo Zhong Xi Yi Jie He Za Zhi), 2009;7, 379-81. (In Chinese)
26. XU H, SHI DZ, YIN HJ, et al. Blood-stasis and Toxin Causing Catastrophe Hypothesis and Acute Cardiovascular Events? Proposal of the Hypothesis and Its Clinical Significance. Chinese Journal of Integrated Traditional and Western Medicine (Zhongguo Zhong Xi Yi Jie He Za Zhi), 2008;28, 934-8. (In Chinese)
27. Xu H, Chen KJ. Inspection on Advantage and Cut-in Point of Integrative Chinese and Western Medicine from View of Cognitive Transition on Atherosclerosis. Chinese Journal of Integrated Traditional and Western Medicine (Zhongguo Zhong Xi Yi Jie He Za Zhi), 2007;27, 5-7. (In Chinese)
28. Xu, H, Gao ZY, Chen KJ. A prospective study on diagnostic and therapeutic and prognosis of the 1864 elderly patients with coronary heart disease. Chinese Journal of Geriatrics (Zhonghua Lao Nian Yi Xue Za Zhi), 2008;27, 617-22. (In Chinese)
29. Chen KJ, Shi DZ, Xu H, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J, 2006;119, 6-13.
30. Li YQ, Jin M, Qiu SL, et al. Effect of Chinese drugs for supplementing Qi, nourishing Yin and activating blood circulation on myocardial perfusion in patients with acute myocardial infarction after revascularization. Chinese Journal of Integrative Medicine, 2009;15, 19-25.
31. Qin F, Huang X. Guanxin II (II) for the management of coronary heart disease. Chinese Journal of Integrative Medicine, 2009;15, 472-6.
32. Zhang YC, Chen RM, Lu BJ, et al. Influence of shengmai capsule on recovery of living capacity in patients after myocardial infarction. Chinese Journal of Integrative Medicine, 2009;15, 333-6.
33. Chu FY, Wang J, Yao KW, et al. Effect of Xuefu Zhuyu Capsule on the symptoms and signs and health-related quality of life in the unstable angina patients with blood-stasis pattern after percutaneous coronary intervention: a randomized controlled trial. Chinese Journal of Integrative Medicine, 2010;16, 301-4.
34. He QY, Wang J, Zhang YL, et al. Effect of Yiqi Yangyin Decoction on the quality of life of patients with unstable angina pectoris. Chinese Journal of Integrative Medicine, 2010;16, 13-8.
35. Gao ZY, Xu H, Shi DZ, et al. Analysis on outcome of 5284 patients with coronary artery disease: The role of integrative medicine. J Ethnopharmacol, doi:10.1016/j.jep. 2011.08.071
36. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet, 2004;363, 892-4.
37. Vigna GB, Fellin R. Pharmacotherapy of dyslipidemia in the adult population. Expert Opin Pharmacother, 2010;11, 3041-52.
38. da Silva PM. Intensive cholesterol drug lowering: how to be sure about their safety. Rev Port Cardiol, 2010;29, 1405-18.
39. Villegas JF, Barabe DN, Stein RA, et al. Adverse effects of herbal treatment of cardiovascular disease: what the physician must know. Heart Dis, 2001;3, 169-75.
40. Chan E, Tan M, Xin J, et al. Interactions between traditional Chinese medicines and Western therapeutics. Curr Opin Drug Discov Devel, 2010;13, 50-65.
41. Wang X, Sun H, Zhang A, et al. Potential role of metabolomics approaches in the area of traditional Chinese medicine: as pillars of the bridge between Chinese and Western medicine. J Pharm Biomed Anal, 2011;55, 859-68.
42. lzzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs, 2009;69(13), 1777-98.
43. Cohen PA, Ernst E. Safety of herbal supplements: a guide for cardiologists. Cardiovasc Ther, 2010;28, 246-53.
44. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol, 2010;55, 515-25.
45. Gupta YK, Briyal S, Gulati A. Therapeutic potential of herbal drugs in cerebral ischemia. Indian J Physiol Pharmacol, 2010;54, 99-122.
46. Chen YF. Traditional Chinese herbal medicine and cerebral ischemia. Front Biosci, 2012;4, 809-17.